Young Hee Yoon1, Jong Woo Kim2, Joo Yong Lee1, In Taek Kim3, Se Woong Kang4, Hyeong Gon Yu5, Hyoung Jun Koh6, Sung Soo Kim6, Dong-Jin Chang7, Susan Simonyi8. 1. Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 2. Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea. 3. Department of Ophthalmology, Kyungpook National University School of Medicine, Daegu, Republic of Korea. 4. Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 5. Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea. 6. Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea. 7. Allergan, Seoul, Republic of Korea. 8. Medical Affairs, Allergan Pte. Ltd., Singapore, Singapore.
Abstract
PURPOSE: To evaluate the effect of dexamethasone intravitreal implant for macular edema (ME) following branch retinal vein occlusion (BRVO) in Korean patients. METHODS: We performed a prospective, open-label, multicenter study of 71 patients with ME for < 3 months. Retreatment was allowed ≥4 months from the last injection. RESULTS: At 6 and 12 months, mean ± SD best-corrected visual acuity (BCVA) improvement was 18.6 ± 12.9 and 15.3 ± 15.0 letters, respectively. Approximately 70% of maximum treatment response was observed after 1 week. Over the 12-month period, 32 and 49% of patients received 1 and 3 injections, respectively, with a mean ± SD interval of 20.0 ± 5.0 weeks. Patients who required 3 injections had higher central retinal thickness (CRT) and larger macular nonperfusion at baseline compared to those requiring only 1 injection. Adverse events included increased intraocular pressure (35%) and newly diagnosed cataract (16%). CONCLUSIONS:Intravitreal dexamethasone treatment with an interval of ≥4 months provides rapid and significantly better improvement in BCVA and CRT in patients with BRVO-associated ME.
RCT Entities:
PURPOSE: To evaluate the effect of dexamethasone intravitreal implant for macular edema (ME) following branch retinal vein occlusion (BRVO) in Korean patients. METHODS: We performed a prospective, open-label, multicenter study of 71 patients with ME for < 3 months. Retreatment was allowed ≥4 months from the last injection. RESULTS: At 6 and 12 months, mean ± SD best-corrected visual acuity (BCVA) improvement was 18.6 ± 12.9 and 15.3 ± 15.0 letters, respectively. Approximately 70% of maximum treatment response was observed after 1 week. Over the 12-month period, 32 and 49% of patients received 1 and 3 injections, respectively, with a mean ± SD interval of 20.0 ± 5.0 weeks. Patients who required 3 injections had higher central retinal thickness (CRT) and larger macular nonperfusion at baseline compared to those requiring only 1 injection. Adverse events included increased intraocular pressure (35%) and newly diagnosed cataract (16%). CONCLUSIONS: Intravitreal dexamethasone treatment with an interval of ≥4 months provides rapid and significantly better improvement in BCVA and CRT in patients with BRVO-associated ME.
Authors: Osman Cekiç; Stanley Chang; Joseph J Tseng; Gaetano R Barile; Lucian V Del Priore; Harold Weissman; William M Schiff; Michael D Ober Journal: Retina Date: 2005 Oct-Nov Impact factor: 4.256
Authors: Peter A Campochiaro; W Lloyd Clark; David S Boyer; Jeffrey S Heier; David M Brown; Robert Vitti; Husain Kazmi; Alyson J Berliner; Kristine Erickson; Karen W Chu; Yuhwen Soo; Yenchieh Cheng; Julia A Haller Journal: Ophthalmology Date: 2014-10-12 Impact factor: 12.079
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li Journal: Ophthalmology Date: 2011-07-20 Impact factor: 12.079
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup Journal: Ophthalmology Date: 2010-04-24 Impact factor: 12.079
Authors: Peter A Campochiaro; Gulnar Hafiz; Syed Mahmood Shah; Quan Dong Nguyen; Howard Ying; Diana V Do; Edward Quinlan; Ingrid Zimmer-Galler; Julia A Haller; Sharon D Solomon; Jennifer U Sung; Yasmin Hadi; Kashif A Janjua; Nida Jawed; David F Choy; Joseph R Arron Journal: Mol Ther Date: 2008-02-05 Impact factor: 11.454
Authors: Juan Lyn Ang; Sarah Ah-Moye; Leah N Kim; Vuong Nguyen; Adrian Hunt; Daniel Barthelmes; Mark C Gillies; Hemal Mehta Journal: Eye (Lond) Date: 2020-04-20 Impact factor: 3.775